1h Free Analyst Time
Neuropathic Pain - Pipeline Review, H2 2019Speak directly to the analyst to clarify any post sales queries you may have.
Summary
This latest Pharmaceutical and Healthcare disease pipeline guide Neuropathic Pain - Pipeline Review, H2 2019, provides an overview of the Neuropathic Pain (Central Nervous System) pipeline landscape.
Neuropathic pain, or neuralgia, is a condition in which the sensory system is affected. It is commonly accompanied by tissue injury. The nerve fibres could be damaged resulting in the generation of abnormal signals. Neuropathic pain is also exhibited along with many other diseases. The symptoms might include shooting pain and numbness. Several factors are involved in causing neuropathic pain however there seems to be no specific reason. Trauma, kidney disease, alcoholism, infections, stress etc may lead to painful symptoms. The condition may be controlled by the use of medications and psychological therapies.
Report Highlights
This Pharmaceutical and Healthcare latest pipeline guide Neuropathic Pain - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Neuropathic Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Neuropathic Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuropathic Pain (Neuralgia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 21, 46, 45, 1, 4, 157, 30 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 3, 34 and 2 molecules, respectively.
Neuropathic Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Neuropathic Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Neuropathic Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neuropathic Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neuropathic Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neuropathic Pain (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neuropathic Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neuropathic Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionNeuropathic Pain (Neuralgia) - Overview
Neuropathic Pain (Neuralgia) - Therapeutics Development
Neuropathic Pain (Neuralgia) - Therapeutics Assessment
Neuropathic Pain (Neuralgia) - Companies Involved in Therapeutics Development
Neuropathic Pain (Neuralgia) - Drug Profiles
Neuropathic Pain (Neuralgia) - Dormant Projects
Neuropathic Pain (Neuralgia) - Discontinued Products
Neuropathic Pain (Neuralgia) - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Neuropathic Pain (Neuralgia), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by 1st Bio Therapeutics Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Abalone Bio Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Achelios Therapeutics Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Acorda Therapeutics Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Adynxx Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by AfaSci Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Affectis Pharmaceuticals AG, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Akelos Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Algiax Pharmaceuticals GmbH, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Algomedix Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Alion Pharmaceuticals Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Allergan Plc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Allodynic Therapeutics LLC, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by AlphaNavi Pharma Co Ltd, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Amgen Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by AnaBios Corp, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Anavex Life Sciences Corp, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Andros Pharmaceuticals Co Ltd, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Angelini Group, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by AngioChem Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Anida Pharma Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by AnyGen Co Ltd, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by AOBiome LLC, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by APT Therapeutics Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Aptarion biotech AG, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Aptinyx Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Aquilus Pharmaceuticals Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Araim Pharmaceuticals Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Arena Pharmaceuticals Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Artelo Biosciences Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Asahi Kasei Pharma Corp, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Asarina Pharma AB, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Astellas Pharma Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Astraea Therapeutics LLC, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by AstraZeneca Plc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Astrocyte Pharmaceuticals Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by AusCann Group Holdings Ltd, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Avanir Pharmaceuticals Inc, H2 2019
Neuropathic Pain (Neuralgia) - Pipeline by Avilex Pharma ApS, H2 2019
List of Figures
Number of Products under Development for Neuropathic Pain (Neuralgia), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 1st Bio Therapeutics Inc
- Abalone Bio Inc
- Achelios Therapeutics Inc
- Acorda Therapeutics Inc
- Adynxx Inc
- AfaSci Inc
- Affectis Pharmaceuticals AG
- Akelos Inc
- Algiax Pharmaceuticals GmbH
- Algomedix Inc
- Alion Pharmaceuticals Inc
- Allergan Plc
- Allodynic Therapeutics LLC
- AlphaNavi Pharma Co Ltd
- Amgen Inc
- AnaBios Corp
- Anavex Life Sciences Corp
- Andros Pharmaceuticals Co Ltd
- Angelini Group
- AngioChem Inc
- Anida Pharma Inc
- AnyGen Co Ltd
- AOBiome LLC
- Aoxing Pharmaceutical Company Inc
- APT Therapeutics Inc
- Aptarion biotech AG
- Aptinyx Inc
- Aquilus Pharmaceuticals Inc
- Araim Pharmaceuticals Inc
- Arena Pharmaceuticals Inc
- Artelo Biosciences Inc
- Asahi Kasei Pharma Corp
- Asarina Pharma AB
- Astellas Pharma Inc
- Astraea Therapeutics LLC
- AstraZeneca Plc
- Astrocyte Pharmaceuticals Inc
- AusCann Group Holdings Ltd
- Avanir Pharmaceuticals Inc
- Avilex Pharma ApS
- Axsome Therapeutics Inc
- BCI Pharma SA
- Bioasis Technologies Inc
- Biodol Therapeutics SAS
- BioElectron Technology Corp
- Biogen Inc
- Biohaven Pharmaceutical Holding Company Ltd
- BioHealthonomics Inc
- Bioiberica SAU
- Blackthorn Therapeutics Inc
- Bol Pharma
- Bsense Bio Therapeutics Ltd
- Calchan Ltd
- Cara Therapeutics Inc
- Cavion LLC
- CCH Pharmaceuticals ApS
- CDA Research Group Inc
- Celgene Corp
- Cellatoz Therapeutics Inc
- Centrexion Therapeutics Corp
- Cerecin Inc
- Cerecor Inc
- CerSci Therapeutics Inc
- Charleston Laboratories Inc
- Chromocell Corp
- Circuit Therapeutics Inc
- Citragen Pharmaceuticals Inc
- Cleveland Diabetes Care Inc
- Clexio Biosciences Ltd
- Coda Biotherapeutics Inc
- Corium International Inc
- Crossject SA
- Cryno LLC
- CrystalGenomics Inc
- Curatis AG
- CURx Pharmaceuticals Inc
- Daewoong Pharmaceutical Co Ltd
- Daiichi Sankyo Co Ltd
- Daya Drug Discoveries Inc
- DelNova Inc
- Dompe Farmaceutici SpA
- Eicosis LLC
- Eli Lilly and Co
- EnhanX Biopharm Inc
- Epalex Corp
- Exodos Life Sciences Limited Partnership
- Expression Drug Designs LLC
- Exxel Pharma Inc
- Four Chuankeruide Pharmaceutical Co Ltd
- GABA Therapeutics Inc
- GB Sciences Inc
- Glialogix Inc
- Grace Therapeutics LLC
- Grunenthal GmbH
- GW Pharmaceuticals Plc
- H. Lundbeck AS
- Hana Pharm Co Ltd
- Helixmith Co Ltd
- Hoba Therapeutics ApS
- ICE Therapeutics Ltd
- Ichnos Sciences Inc
- Imbrium Therapeutics LP
- Immune Pharmaceuticals Inc
- Impel NeuroPharma Inc
- Initiator Pharma AS
- InKemia IUCT Group SA
- InMed Pharmaceuticals Inc
- InStar Technologies AS
- Intec Pharma Ltd
- Integral Molecular Inc
- IntelGenx Corp
- Intellipharmaceutics International Inc
- Invisio Ltd
- Ionis Pharmaceuticals Inc
- Ipsen SA
- iQure Pharma Inc
- Jeil Pharmaceutical Co Ltd
- Jiangsu Nhwa Pharmaceutical Corp Ltd
- Johnson & Johnson
- JT Pharmaceuticals Inc
- Kancera AB
- KannaLife Sciences Inc
- Kineta Inc
- Klaria Pharma Holding AB
- Knopp Biosciences LLC
- Kolon Life Science Inc
- Komipharm International Co Ltd
- Krisani Bio Sciences Pvt Ltd
- Lateral Pharma Pty Ltd
- Lexicon Pharmaceuticals Inc
- Living Cell Technologies Ltd
- Lohocla Research Corp
- Luye Pharma Group Ltd
- MannKind Corp
- Mapi Pharma Ltd
- MD Biosciences GmbH
- Medifron DBT Co Ltd
- MEDRx Co Ltd
- Medytox Inc
- Merck & Co Inc
- Merz Pharma GmbH & Co KgaA
- MindImmune Therapeutics Inc
- Mitsubishi Tanabe Pharma Corp
- Mundipharma International Ltd
- NAL Pharmaceuticals Ltd
- Nanomerics Ltd
- NeurAxon Pharma Inc
- Neurim Pharmaceuticals Ltd
- Neuro Vigor LLC
- NeuroCycle Therapeutics GmbH
- Neurodyn Life Sciences Inc
- NeuroFix Therapeutics LLC
- Neurona Therapeutics Inc
- NeurOp Inc
- NeuroPn Therapeutics LLC
- NeuroTherpia Inc
- Newron Pharmaceuticals SpA
- Nippon Chemiphar Co Ltd
- Nippon Zoki Pharmaceutical Co Ltd
- NoNO Inc
- Novaremed AG
- Novassay SA
- Noveome Biotherapeutics Inc
- NutriBand Inc
- OKYO Pharma Ltd
- Old API Wind-down Ltd
- OliPass Corporation
- OliX Pharmaceuticals Inc
- Orexigen Therapeutics Inc
- OWP Pharmaceuticals Inc
- Panag Pharma Inc
- Panaxia Pharmaceutical Industries Ltd
- Paracelsus Neuroscience I LLC
- Patagonia Pharmaceuticals LLC
- Pharmaleads SA
- Pharmnovo AB
- Phosphagenics Ltd
- Pivot Pharmaceuticals Inc
- PixarBio Corp
- PlantForm Corp
- Priavoid GmbH
- PRISM Pharma Co Ltd
- Promius Pharma LLC
- ProNeurogen Inc
- Qingdao Chia Tai Haier Pharmaceutical Co Ltd
- RAFT Pharmaceuticals
- RaQualia Pharma Inc
- Re-Pharm Ltd
- Regeneus Ltd
- Relieve Genetics Inc
- Revance Therapeutics Inc
- Romark Laboratories LC
- Rottapharm Biotech Srl
- Saniona AB
- Sarfez Pharmaceuticals Inc
- Satsuma Pharmaceuticals Inc
- Scientus Pharma Inc
- Scilex Holding Co
- Serentrix LLC
- Seurat Therapeutics Inc
- Shanghai Junshi Bioscience Co Ltd
- Shanghai SIMR Biotech Co Ltd
- Shenox Pharmaceuticals LLC
- Shin Nippon Biomedical Laboratories Ltd
- Shionogi & Co Ltd
- Sichuan Haisco Pharmaceutical Co Ltd
- Signal Pharma Ltd
- Sollis Therapeutics Inc
- Sorrento Therapeutics Inc
- Sosei Heptares
- SpineThera Inc
- Stem Cell Medicine Ltd
- Suda Pharmaceuticals Ltd
- Sumitomo Dainippon Pharma Co Ltd
- Synerkine Pharma BV
- Syntrix Biosystems Inc
- Techfields Pharma Co Ltd
- Terran Biosciences Inc
- Teva Pharmaceutical Industries Ltd
- Theranexus SAS
- Titan Pharmaceuticals Inc
- Topical Innovations BV
- Toray Industries Inc
- Trevena Inc
- TrioxBio Inc
- Vertex Pharmaceuticals Inc
- Virobay Inc
- VistaGen Therapeutics Inc
- Vitality Biopharma Inc
- Winston Pharmaceuticals Inc
- Xalud Therapeutics Inc
- Xoc Pharmaceuticals Inc
- Yantai YenePharma Co Ltd
- Yooyoung Pharm Co Ltd
- Yuhan Corp
- Zosano Pharma Corp
